Mitral regurgitation resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 84: Line 84:
:❑ [[Crackles]] or [[rales]] <br>
:❑ [[Crackles]] or [[rales]] <br>
❑ [[Cardiogenic shock physical examination|Signs and symptoms of cardiogenic shock]]: <BR>
❑ [[Cardiogenic shock physical examination|Signs and symptoms of cardiogenic shock]]: <BR>
:❑ [[Tachycardia]] <br>
:❑ [[Hypotension]]<br>
:❑ [[Altered mental status]]<br>
:❑ [[Altered mental status]]<br>
:❑ [[Oliguria]]<br>
:❑ [[Oliguria]]<br>
:❑ [[Cyanosis]]
:❑ [[Diaphoresis]]
:❑ [[Diaphoresis]]
:❑ [[Tachycardia]] <br>
:❑ [[Cold extremities]]
:❑ [[Hypotension]]<br>
:❑ [[Peripheral cyanosis]]
:❑ [[Mottling]]
</div>}}
</div>}}
{{familytree  | | | | | | | |,|-|^|-|.| | | | |}}
{{familytree  | | | | | | | |,|-|^|-|.| | | | |}}
Line 96: Line 98:
{{familytree  | | | | | | | |!| | | A02 | | | | | | A02= [[Mitral regurgitation resident survival guide#Complete Diagnostic Approach|'''Continue with complete diagnostic approach below''']]}}
{{familytree  | | | | | | | |!| | | A02 | | | | | | A02= [[Mitral regurgitation resident survival guide#Complete Diagnostic Approach|'''Continue with complete diagnostic approach below''']]}}
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | | A01 | | | | | |  A01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Initiate resuscitative measures:'''<br>
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | | A01 | | | | | |  A01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Initiate resuscitative measures:'''<br>
----
❑ Secure airway <br>
❑ Secure airway <br>
❑ O2 <br>
Administer O2 <br>
❑ 2 wide bore IV access <br>
Establish 2 wide bore IV access <br>
Arterial line<br>
Establish an arterial line<br>
❑ ECG monitor<br>
Connect to ECG monitor<br>
❑ Monitor vitals continuously<br>
❑ Monitor vitals continuously<br>
❑ ICU admission<br>
Consider ICU admission<br>
❑ Consider [[mechanical ventilation|<span style="color:white;">mechanical ventilation</span>]]<br>
❑ Consider [[mechanical ventilation|<span style="color:white;">mechanical ventilation</span>]]<br>
❑ Consider [[pulmonary artery catheterization|<span style="color:white;">pulmonary artery catheterization</span>]]
❑ Consider [[pulmonary artery catheterization|<span style="color:white;">pulmonary artery catheterization</span>]]
----
----
'''Order imaging and blood tests (urgent):'''<br>
'''Order imaging and blood tests (urgent):'''<br>
----
❑ [[Transthoracic echocardiography|<span style="color:white;">Transthoracic echocardiography</span>]] ([[TTE|<span style="color:white;">TTE</span>]])<br>
❑ [[Transthoracic echocardiography|<span style="color:white;">Transthoracic echocardiography</span>]] ([[TTE|<span style="color:white;">TTE</span>]])<br>
❑ [[Chest X-ray|<span style="color:white;">Chest X-ray</span>]]<br>
❑ [[Chest X-ray|<span style="color:white;">Chest X-ray</span>]]<br>
❑ [[CBC|<span style="color:white;">CBC</span>]] <br>
❑ [[CBC|<span style="color:white;">CBC</span>]] <br>
❑ [[Serum electrolytes|<span style="color:white;">Serum electrolytes</span>]]<br>
❑ [[Serum electrolytes|<span style="color:white;">Serum electrolytes</span>]]<br>
❑ [[Blood cultures|<span style="color:white;">Blood cultures</span>]] (in case of fever)  <br>
❑ Serum cardiac [[troponin|<span style="color:white;">troponin</span>]] I and T  <br>
❑ Serum cardiac [[troponin|<span style="color:white;">troponin</span>]] I and T  <br>
❑ [[Creatine kinase|<span style="color:white;">Creatine kinase</span>]] (CK-MB)  <br>
❑ [[Creatine kinase|<span style="color:white;">Creatine kinase</span>]] (CK-MB)  <br>
Line 118: Line 119:
</div>}}
</div>}}
{{familytree  | | | | | | | |!| | | | | | }}
{{familytree  | | | | | | | |!| | | | | | }}
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | | A01 | | | | | A01=Is there any evidence of MR in TTE}}  
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | | A01 | | | | | A01='''Does the patient has any evidence of MR in TTE?'''}}  
{{familytree  | | | | | |,|-|^|-|.| | | | }}  
{{familytree  | | | | | |,|-|^|-|.| | | | }}  
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | A01 | | A02 | | | A01=Yes| A02=No}}
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | A01 | | A02 | | | A01=Yes| A02=No}}
{{familytree  | | | | | |!| | | |!| | | | }}  
{{familytree  | | | | | |!| | | |!| | | | }}  
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | A01 | | A02 | | | A01= <div style="text-align: left; width: 18em; padding: 1em;">
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | A01 | | A02 | | | A01= <div style="text-align: left; width: 18em; padding: 1em;">
'''Initiate medical therapy:'''<br>
'''Stabilize the patient:'''<br>
Initiate medical stabilization:
:❑ [[Vasodilator|<span style="color:white;">Vasodilator</span>]] (IV [[nitroprusside|<span style="color:white;">nitroprusside</span>]]) '''PLUS''' inotropic agents (IV [[dobutamine|<span style="color:white;">dobutamine</span>]]) <br>
❑ Establish [[intra-aortic balloon pump|<span style="color:white;">intra-aortic balloon pump</span>]]:<br>
:❑ If medical therapy is not effective to maintain hemodynamic stability<br>
----
----
❑ [[Vasodilator|<span style="color:white;">Vasodilator</span>]] (IV [[nitroprusside|<span style="color:white;">nitroprusside</span>]]) '''PLUS''' inotropic agents (IV [[dobutamine|<span style="color:white;">dobutamine</span>]]) <br>
'''Initiate treatment for specific etiologies:'''<br>
❑ [[Aspirin|<span style="color:white;">Aspirin</span>]] in case of myocardial infarction<br>
❑ [[Aspirin|<span style="color:white;">Aspirin</span>]] in case of myocardial infarction<br>
❑ Antibiotics in case of [[Infective endocarditis resident survival guide|<span style="color:white;">infective endocarditis</span>]]  
❑ Antibiotics in case of [[Infective endocarditis resident survival guide|<span style="color:white;">infective endocarditis</span>]]  
----
</div>| A02= <div style="text-align: left; width: 18em; padding: 1em;">'''Consider other possible diagnosis:'''<br>
'''[[Intra-aortic balloon pump|<span style="color:white;">Intra-aortic balloon pump</span>]]:'''<br>
----
❑ If medical therapy is not effective to maintain hemodynamic stability<br>
❑ Effective especially in case of ischemic mitral regurgitation</div>| A02= <div style="text-align: left; width: 18em; padding: 1em;">'''Consider other possible diagnosis:'''<br>
----
❑ [[Acute respiratory distress syndrome|<span style="color:white;">Acute respiratory distress syndrome</span>]]  
❑ [[Acute respiratory distress syndrome|<span style="color:white;">Acute respiratory distress syndrome</span>]]  
❑ [[Sepsis|<span style="color:white;">Sepsis</span>]]<br>
❑ [[Sepsis|<span style="color:white;">Sepsis</span>]]<br>
</div>}}
</div>}}
{{familytree  | | | | | |!| | | | | | }}  
{{familytree  | | | | | |!| | | | | | }}  
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | A01 | | | | | | A01= <div style="text-align: left; width: 18em; padding: 1em;">'''Does the patient have any findings on TTE that require mitral valve surgery:'''<br>
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | A01 | | | | | | A01= <div style="text-align: left; width: 18em; padding: 1em;">'''Does the patient have any findings on TTE that require mitral valve surgery?'''<br>
----
❑ Flail mitral leaflet (papillary muscle or chordal rupture)<br>
❑ Flail mitral leaflet (papillary muscle or chordal rupture)<br>
❑ Any signs of [[endocarditis|<span style="color:white;">endocarditis</span>]] <br>
❑ Any signs of [[endocarditis|<span style="color:white;">endocarditis</span>]] <br>
Line 148: Line 147:
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | A01 | | A02 | | | | A01=Yes| A02=No}}
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | A01 | | A02 | | | | A01=Yes| A02=No}}
{{familytree  | | | |!| | | |!| | | | | }}  
{{familytree  | | | |!| | | |!| | | | | }}  
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | A01 | | A02 | | | | A01=<div style="text-align: left; width: 18em; padding: 1em;">'''Mitral valve surgery:'''<br>
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | A01 | | A02 | | | | A01=<div style="text-align: left; width: 18em; padding: 1em;">'''Perform mitral valve surgery:'''<br>
----
❑ [[Mitral valve repair|<span style="color:white;">Mitral valve repair</span>]]: <br>
❑ [[Mitral valve repair|<span style="color:white;">Mitral valve repair</span>]]: <br>
:❑ Most preferred
:❑ Most preferred
:❑ Done in absence of [[papillary muscle|<span style="color:white;">papillary muscle</span>]] necrosis
:❑ Done in absence of [[papillary muscle|<span style="color:white;">papillary muscle</span>]] necrosis
❑ [[Mitral valve replacement|<span style="color:white;">Mitral valve replacement</span>]]:
❑ [[Mitral valve replacement|<span style="color:white;">Mitral valve replacement</span>]]:
:❑ In complex MR with extensive destruction
:❑ Performed in cases of complex MR with extensive tissue destruction
:❑ Lateral LV wall motion abnormality  
:❑ Performed in cases of MR with lateral LV wall motion abnormality  
</div>| A02=<div style="text-align: left; width: 18em; padding: 1em;">'''Reperfusion or revascularization:'''<br>
</div>| A02=<div style="text-align: left; width: 18em; padding: 1em;">'''Perform reperfusion or revascularization:'''<br>
----
----
❑ In patients with acute coronary syndrome, [[CABG|<span style="color:white;">CABG</span>]] or [[coronary angioplasty|<span style="color:white;">coronary angioplasty</span>]] should be performed<br>
❑ Early reperfusion for [[myocardial infarction|<span style="color:white;">myocardial infarction</span>]] can reduce localized [[LV|<span style="color:white;">LV</span>]] remodeling and hence [[MR|<span style="color:white;">MR</span>]]
❑ Early reperfusion for [[myocardial infarction|<span style="color:white;">myocardial infarction</span>]] can reduce localized [[LV|<span style="color:white;">LV</span>]] remodeling and hence [[MR|<span style="color:white;">MR</span>]]
❑ [[CABG|<span style="color:white;">CABG</span>]] or [[coronary angioplasty|<span style="color:white;">coronary angioplasty</span>]] <br>
 
</div>}}  
</div>}}  
{{familytree  | | | |!| | | | | | | | }}  
{{familytree  | | | |!| | | | | | | | }}  
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | A01 | | | | | | A01=<div style="text-align: left; width: 18em; padding: 1em;">'''Reperfusion or revascularization:'''<br>
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | A01 | | | | | | A01=<div style="text-align: left; width: 18em; padding: 1em;">'''Perform reperfusion or revascularization:'''<br>
----
Perform [[CABG|<span style="color:white;">CABG</span>]] or [[coronary angioplasty|<span style="color:white;">coronary angioplasty</span>]] at the time of mitral valve surgery in patients with myocardial infarction<br>
❑ For MR due to [[myocardial infarction|<span style="color:white;">myocardial infarction</span>]]
❑ [[CABG|<span style="color:white;">CABG</span>]] or [[coronary angioplasty|<span style="color:white;">coronary angioplasty</span>]] <br>
----
'''Cardiac transplantation:'''<br>
----
----
'''Consider cardiac transplantation:'''<br>
❑ On some occasions with no contraindication for surgery<br>
❑ On some occasions with no contraindication for surgery<br>
In patients with severe LV dysfunction  
For patients with severe LV dysfunction  
</div>}}
</div>}}
{{Family tree/end}}
{{Family tree/end}}


==Complete Diagnostic Approach to Mitral Regurgitation==
==Complete Diagnostic Approach to Mitral Regurgitation==
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.  Shown below is an algorithm summarizing the complete diagnostic approach to mitral regurgitation according to 2014 AHA/ACC guidelines for management of valvular heart disease.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
<span style="font-size:85%">'''Abbreviations:''' '''AF''': Atrial fibrillation; '''MR''': Mitral regurgitation; '''EKG''': Electrocardiogram; '''EF''': Ejection fraction; '''S1''': First heart sound; '''S2''': Second heart sound; '''S3''': Third heart sound; '''LV''': Left ventricle; '''MVP''': Mitral valve prolapse</span> <br>
<span style="font-size:85%">'''Abbreviations:''' '''AF''': Atrial fibrillation; '''MR''': Mitral regurgitation; '''EKG''': Electrocardiogram; '''EF''': Ejection fraction; '''S1''': First heart sound; '''S2''': Second heart sound; '''S3''': Third heart sound; '''LV''': Left ventricle; '''MVP''': Mitral valve prolapse</span> <br>


{{family tree/start}}
{{family tree/start}}
{{family tree| | | | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width:25em; padding:1em;">'''Characterize the symptoms:'''<br>
{{family tree| | | | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width:25em; padding:1em;">'''Characterize the symptoms:'''<br>
----
'''Acute mitral regurgitation:'''
'''Acute mitral regurgitation:'''
----
❑ '''Symptoms of [[shock]] and [[pulmonary edema]]:'''<br>
❑ '''Symptoms of [[shock]] and [[pulmonary edema]]:'''<br>
:❑ [[Shortness of breath]]<br>
:❑ [[Shortness of breath]]<br>
Line 201: Line 195:
----
----
'''Chronic mitral regurgitation:'''
'''Chronic mitral regurgitation:'''
----
❑ [[Asymptomatic]]  
❑ [[Asymptomatic]]  
:❑ Typical in isolated mild to moderate [[MR]]
:❑ Typical in isolated mild to moderate [[MR]]
:❑ Severe MR until there is [[left ventricular failure]], [[pulmonary hypertension]] or [[atrial fibrillation]]
:❑ Severe MR until there is [[left ventricular failure]], [[pulmonary hypertension]] or [[atrial fibrillation]]
❑ '''Symptoms associated with decreased forward flow and increased backflow across mitral valve:'''<br>
❑ '''Symptoms associated with decreased forward flow and increased backflow across mitral valve (left ventricular failure):'''<br>
:❑ [[Exertional dyspnea]]<br>
:❑ [[Exertional dyspnea]]<br>
:❑ [[Orthopnea]]<br>
:❑ [[Orthopnea]]<br>
Line 227: Line 220:
::❑ [[edema|Pedel edema]]
::❑ [[edema|Pedel edema]]
::❑ [[Abdominal pain]] ([[hepatomegaly]])
::❑ [[Abdominal pain]] ([[hepatomegaly]])
❑ '''Other etiology associated symptoms:'''<br>
:❑ [[Joint pains]] (suggestive of rheumatic etiology)<br>
:❑ Skin lesions (suggestive of rheumatic etiology)<br>
  </div>}}
  </div>}}
{{family tree| | | | | | | |!| | | | | | }}
{{family tree| | | | | | | |!| | | | | | }}
Line 303: Line 293:


'''Abdominal system:''' <br>
'''Abdominal system:''' <br>
[[Hepatojugular reflex]]<br>
❑ Hepatojugular reflex<br>
❑ [[Hepatomegaly]] <br>
❑ [[Hepatomegaly]] <br>
❑ [[Ascites]]<br>
❑ [[Ascites]]<br>
Line 312: Line 302:
{{Family tree| | | | | | | |!| | | | | | }}
{{Family tree| | | | | | | |!| | | | | | }}
{{Family tree| | | | | | | D01 | | | | | D01= <div style="float: left; text-align: left; width:25em; padding:1em;">'''Order [[electrocardiogram]] (urgent):'''  
{{Family tree| | | | | | | D01 | | | | | D01= <div style="float: left; text-align: left; width:25em; padding:1em;">'''Order [[electrocardiogram]] (urgent):'''  
----
❑ In [[MR|acute MR]]<br>
❑ In [[MR|acute MR]]<br>
:❑ Mostly normal
:❑ Mostly normal
Line 322: Line 311:
:❑ Findings of [[Atrial fibrillation electrocardiogram|atrial fibrillation]] complication
:❑ Findings of [[Atrial fibrillation electrocardiogram|atrial fibrillation]] complication
[[Image:P mitrale.gif|center|150px|thumb|Left atrial enlargement produces a broad, bifid P wave in lead II ('''P mitrale''')]]
[[Image:P mitrale.gif|center|150px|thumb|Left atrial enlargement produces a broad, bifid P wave in lead II ('''P mitrale''')]]
----
 
'''Order [[chest X-ray]] (urgent):'''<br>
'''Order [[chest X-ray]] (urgent):'''<br>
----
❑ [[MR|Acute MR]]<br>
❑ [[MR|Acute MR]]<br>
:❑ Normal size cardiac silhouette  
:❑ Normal size cardiac silhouette  
Line 334: Line 322:


[[Image:mitral-valve02.jpg|150px|center|thumb|Calcification of the mitral annulus around the margins of the posterior leaflet forming a “C”]]<br clear="left"/>
[[Image:mitral-valve02.jpg|150px|center|thumb|Calcification of the mitral annulus around the margins of the posterior leaflet forming a “C”]]<br clear="left"/>
----
 
'''Order [[transthoracic echocardiography]] ([[TTE]]) (urgent):'''<br>
'''Order [[transthoracic echocardiography]] ([[TTE]]) (urgent):'''<br>
----
❑ Confirmatory<br>
❑ Confirmatory<br>
❑ To determine severity and assess hemodynamic consequences <br>
❑ To determine severity and assess hemodynamic consequences <br>
❑ To establish etiology<br>
❑ To establish etiology<br>
❑ To determine prognosis and evaluate for timing of intervention
❑ To determine prognosis and evaluate for timing of intervention
----
 
'''Order lab tests:'''<br>
'''Order lab tests:'''<br>
----
❑ [[CBC]]<br>
❑ [[CBC]]<br>
❑ [[Electrolytes]] <br>
❑ [[Electrolytes]] <br>
Line 349: Line 335:
❑ [[Troponin|Serum cardiac troponin I and T]]  <br>
❑ [[Troponin|Serum cardiac troponin I and T]]  <br>
❑ [[Creatine kinase]] (CK-MB)  <br>
❑ [[Creatine kinase]] (CK-MB)  <br>
❑ [[Blood cultures]] (in case of fever)  <br>
❑ Serum [[urea]] and [[creatinine]]  <br>
❑ Serum [[urea]] and [[creatinine]]  <br>
----
 
'''Other tests'''<br>
'''Other tests:'''<br>
----
❑ [[Transesophageal echocardiography]] ([[TEE]] if [[TTE]] is equivocal)<br>
❑ [[Transesophageal echocardiography]] ([[TEE]] if [[TTE]] is equivocal)<br>
❑ [[Cardiac catheterization]]:<br>
❑ [[Cardiac catheterization]]:<br>
Line 364: Line 350:
❑ [[MRI|Cardiac MRI]]<br>
❑ [[MRI|Cardiac MRI]]<br>
:❑ To assess severity when there is a discrepancy between clinical findings and [[echocardiography]]</div>}}
:❑ To assess severity when there is a discrepancy between clinical findings and [[echocardiography]]</div>}}
{{familytree | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | A01='''Does the patient has acute or chronic [[MR]]?'''}}
{{Family tree| | | |,|-|-|-|^|-|-|-|.| | }}
{{Family tree| | | |,|-|-|-|^|-|-|-|.| | }}
{{Family tree| | | F01 | | | | | | F02 | | | F01=<div style="float: left; text-align: left; width:25em; padding:1em;">'''Cardinal findings that are suggestive of [[MR|acute mitral regurgitation]]'''<br>
{{Family tree| | | F01 | | | | | | F02 | | | F01=<div style="float: left; text-align: left; width:25em; padding:1em;">'''Acute MR (Cardinal findings suggestive of [[MR|acute mitral regurgitation]])'''<br>
❑ Sudden onset and rapid progression of [[pulmonary edema]]<br>
❑ Sudden onset and rapid progression of [[pulmonary edema]]<br>
❑ [[Cardiogenic shock physical examination|Signs and symptoms of cardiogenic shock]] <BR>
❑ [[Cardiogenic shock physical examination|Signs and symptoms of cardiogenic shock]] <BR>
Line 376: Line 364:
:❑ Reduced EF
:❑ Reduced EF
:❑ Ruptured mitral [[chordae tendinae]] (flail leaflet)
:❑ Ruptured mitral [[chordae tendinae]] (flail leaflet)
:❑ Ruptured [[papillary muscle]]</div>| F02=<div style="float: left; text-align: left; width:25em; padding:1em;">'''Cardinal findings that are suggestive of [[MR|chronic mitral regurgitation]]'''<br>
:❑ Ruptured [[papillary muscle]]</div>| F02=<div style="float: left; text-align: left; width:25em; padding:1em;">'''Chronic MR (cardinal findings suggestive of [[MR|chronic mitral regurgitation]])'''<br>
❑ Asymptomatic to chronic symptoms<br>
❑ Asymptomatic to chronic symptoms<br>
❑ Pre-existing [[heart disease]]<br>
❑ Pre-existing [[heart disease]]<br>
Line 387: Line 375:
:❑ Preserved to decreased [[EF]]</div>}}
:❑ Preserved to decreased [[EF]]</div>}}
{{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | F02 | | | | | | | | | | | | | | | | | | | | | F02=[[Mitral valve]] anatomy}}
{{familytree | | | | | | | | | | | F02 | | | | | | | | | | | | | | | | | | | | | F02='''Does the [[mitral valve]] anatomy appear normal in [[TTE]]?'''}}
{{Family tree| | | | | | | | | |,|-|^|-|.| |}}
{{Family tree| | | | | | | | | |,|-|^|-|.| |}}
{{familytree | | | | | | | | | G01 | | G02 | | | | | | | | | | | | | | | | | | | G01=Normal| G02=Abnormal}}
{{familytree | | | | | | | | | G01 | | G02 | | | | | | | | | | | | | | | | | | | G01=Yes| G02=No}}
{{familytree | | | | | | | | | |!| | | |!| | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | |!| | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | G01 | | G02 | | | | | | | | | | | | | | | | | | | G01=Chronic primary [[mitral regurgitation]]| G02=Chronic secondary [[mitral regurgitation]]}}
{{familytree | | | | | | | | | G01 | | G02 | | | | | | | | | | | | | | | | | | | G02=Chronic primary [[mitral regurgitation]]| G01=Chronic secondary [[mitral regurgitation]]}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree/end}}
{{familytree/end}}
Line 398: Line 386:
===Treatment of Acute Mitral Regurgitation===
===Treatment of Acute Mitral Regurgitation===
Shown below is an algorithm summarizing the approach to the management of acute mitral regurgitation.<ref name="pmid19564568">{{cite journal| author=Stout KK, Verrier ED| title=Acute valvular regurgitation. | journal=Circulation | year= 2009 | volume= 119 | issue= 25 | pages= 3232-41 | pmid=19564568 | doi=10.1161/CIRCULATIONAHA.108.782292 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19564568  }} </ref><ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
Shown below is an algorithm summarizing the approach to the management of acute mitral regurgitation.<ref name="pmid19564568">{{cite journal| author=Stout KK, Verrier ED| title=Acute valvular regurgitation. | journal=Circulation | year= 2009 | volume= 119 | issue= 25 | pages= 3232-41 | pmid=19564568 | doi=10.1161/CIRCULATIONAHA.108.782292 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19564568  }} </ref><ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
<span style="font-size:85%">'''Abbreviations:'''  '''IE''': Infective endocarditis; '''LV''': Left ventricle; '''LVEF''': Left ventricular ejection fraction; '''MR''': Mitral regurgitation; </span> <br>
<span style="font-size:85%">'''Abbreviations:'''  '''IE''': Infective endocarditis; '''LV''': Left ventricle; '''LVEF''': Left ventricular ejection fraction; '''MR''': Mitral regurgitation </span> <br>


{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | |A01=[[MR|Acute mitral regurgitation]]}}
{{familytree | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | | | |B01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Does the patient has any signs of hemodynamic instability?''' <br>
{{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | | | |B01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Assess if the patient is hemodynamically stable?''' <br>
❑ Hemodynamic instability
❑ Hemodynamic instability
:❑ [[Hypotension]]
:❑ [[Hypotension]]
Line 413: Line 399:
{{familytree | | | | | C01 | | | | C02 | | | | | | | | | | | | | | | | | | | | |C01='''Yes'''<br>(unstable)|C02='''No'''<br>(stable)}}
{{familytree | | | | | C01 | | | | C02 | | | | | | | | | | | | | | | | | | | | |C01='''Yes'''<br>(unstable)|C02='''No'''<br>(stable)}}
{{familytree | | | | | |!| | | | | |!| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | |!| | | | | |!| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | D01 | | | | D02 | | | | | | | | | | | | | | | | | | | | |D01=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Initial resuscitative measures:'''<br>
{{familytree | | | | | D01 | | | | D02 | | | | | | | | | | | | | | | | | | | | |D01=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Initiate resuscitative measures:'''<br>
----
❑ Secure airway <br>
❑ Secure airway <br>
❑ O2 <br>
Administer O2 <br>
❑ 2 wide bore IV access <br>
Establish 2 wide bore IV access <br>
Arterial line<br>
Establish an arterial line<br>
❑ ECG monitor<br>
Connect to ECG monitor<br>
❑ Monitor vitals continuously<br>
❑ Monitor vitals continuously<br>
❑ ICU admission
Consider ICU admission<br>
----
Consider [[Mechanical ventilation]]<br>
'''Initiate medical therapy:'''<br>
Consider [[Pulmonary artery catheterization]]
----
❑ [[Vasodilator]] therapy: IV [[nitroprusside]]<br>
'''AND'''<br>
Inotropic agents: IV [[dobutamine]]<br>
----
----
'''Consider the following:'''<br>
'''Stabilize the patient:'''<br>
----
❑ Initiate medical stabilization:
❑ [[Mechanical ventilation]]<br>
:❑ [[Vasodilator]] (IV [[nitroprusside]]) '''PLUS''' inotropic agents (IV [[dobutamine]]) <br>
❑ [[Pulmonary artery catheterization]]</div>| D02=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Initial resuscitative measures:'''<br>
Establish [[intra-aortic balloon pump]]:<br>
----
:❑ If medical therapy is not effective to maintain hemodynamic stability<br>
❑ O2 <br>
</div>| D02=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Initiate resuscitative measures:'''<br>
❑ 2 wide bore IV access <br>
Administer O2 <br>
Establish 2 wide bore IV access <br>
❑ Connect to ECG monitor<br>
❑ Monitor vitals continuously<br>
❑ Monitor vitals continuously<br>
----
----
'''Initiate medical therapy:'''<br>
'''Initiate medical therapy:'''<br>
----
❑ [[Vasodilator]] therapy: IV  [[nitroprusside]]<br></div>}}
❑ [[Vasodilator]] therapy: IV  [[nitroprusside]]<br></div>}}
{{familytree | | | | | |`|-|-|v|-|-|'| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | |`|-|-|v|-|-|'| | | | | | | | | | | | | | | | | | | | | | }}
Line 447: Line 429:
{{familytree | | | | | |!| | | I02 | | I03 | | | | | | | | | | | | | | | | | | | | I02=[[MR]] due to heart failure  exacerbation(functional [[MR]])| I03= [[MR]] due to [[IE]] (organic [[MR]])}}
{{familytree | | | | | |!| | | I02 | | I03 | | | | | | | | | | | | | | | | | | | | I02=[[MR]] due to heart failure  exacerbation(functional [[MR]])| I03= [[MR]] due to [[IE]] (organic [[MR]])}}
{{familytree | | | | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | E01 | | E02 | | E03 | | | | | | | | | | | | | | | | |E01=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Initiate medical therapy:'''<br>
{{familytree | | | | | E01 | | E02 | | E03 | | | | | | | | | | | | | | | | |E01=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Perform reperfusion or revascularization surgery:'''<br>
----
❑ [[CABG]] or [[coronary angioplasty]] should be done for acute coronary syndrome  <br>
❑ In cases of reduced LVEF (ischemic cardiomyopathy)<br>
❑ Medications: <br>
:❑ [[Angiotensin converting enzyme inhibitors]]
:❑ [[Angiotensin II receptor blockers]]<br>
:❑ [[Beta blockers]]
----
'''[[Intra-aortic balloon pump]]:'''<br>
----
❑ To improve forward [[cardiac output]]<br>
❑ To reduce the impact on regurgitant volume
----
'''Reperfusion or revascularization:'''<br>
----
❑ [[CABG]] or [[coronary angioplasty]] <br>
❑ Early reperfusion can reduce localized [[LV]] remodeling and hence [[MR]]<br>
❑ Early reperfusion can reduce localized [[LV]] remodeling and hence [[MR]]<br>
----
 
'''Mitral valve surgery:'''<br>
'''Consider mitral valve surgery:'''<br>
----
❑ Indications of mitral valve surgery in ischemic MR:
❑ [[Papillary muscle rupture]]<br>
:❑ [[Papillary muscle rupture]]<br>
❑ Moderate to severe [[ischemic MR]] who are undergoing [[CABG]]<br>
:❑ Moderate to severe [[ischemic MR]] who are undergoing [[CABG]]<br>
❑ [[Mitral valve repair]]: <br>
❑ [[Mitral valve repair]]: <br>
:❑ Most preferred
:❑ Most preferred
Line 475: Line 443:
:❑ In complex [[MR]] with extensive destruction
:❑ In complex [[MR]] with extensive destruction
:❑ Lateral [[LV]] wall motion abnormality  
:❑ Lateral [[LV]] wall motion abnormality  
----
 
'''Cardiac transplantation:'''<br>
'''Consider medical therapy:'''<br>
❑ In cases of reduced LVEF (ischemic cardiomyopathy)<br>
❑ Medications: <br>
:❑ [[Angiotensin converting enzyme inhibitors]]
:❑ [[Angiotensin II receptor blockers]]<br>
:❑ [[Beta blockers]]
 
'''Consider cardiac transplantation:'''<br>
----
----
❑ On some occasions with no contraindication for surgery<br>
❑ On some occasions with no contraindication for surgery<br>
❑ In patients with severe [[LV]] dysfunction  
❑ In patients with severe [[LV]] dysfunction  
</div>| E02=<div style="float: left; text-align: left; width: em; padding:1em;">'''Initiate heart failure therapy:''' <br>
</div>| E02=<div style="float: left; text-align: left; width: em; padding:1em;">'''Initiate treatment for heart failure:''' <br>
----
❑ Click [[Acute heart failure resident survival guide|here]] for acute heart failure resident survival guide
❑ Click [[Acute heart failure resident survival guide|here]] for acute heart failure resident survival guide
:❑ [[ACE inhibitors]] or ([[ARBs]]) if LVEF is ≤ 40%
:❑ [[ACE inhibitors]] or ([[ARBs]]) if LVEF is ≤ 40%
Line 488: Line 462:
:❑ [[Diuretic ]]therapy  
:❑ [[Diuretic ]]therapy  
:❑ IV [[vasodilators]]
:❑ IV [[vasodilators]]
----
</div>| E03=<div style="float: left; text-align: left; width: 16em; padding:1em;">
'''Mitral valve surgery:'''<br>
----
❑ When there is no response to medical management
❑ [[Mitral valve replacement]] or [[mitral valve repair]] </div>| E03=<div style="float: left; text-align: left; width: 16em; padding:1em;">
'''Initiate medical therapy:'''<br>
'''Initiate medical therapy:'''<br>
----
----
Line 510: Line 480:
:❑ If less [[mitral valve]] destruction
:❑ If less [[mitral valve]] destruction
</div>}}
</div>}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | A01=Does the patient show any hemodynamic improvement to medical therapy }}
{{familytree | | | | | | | |,|-|^|-|.| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | A01 | | A02 | | | | | | | | | | | | | | | | | | | | A01=Yes|A02=No}}
{{familytree | | | | | | | |!| | | |!| | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | A01 | | A02 | | | | | | | | | | | | | | | | | | | | A01= Continue with the heart failure management and have appropriate follow ups to assess the severity of MR| A02=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Consider mitral valve surgery:'''<br>
❑ [[Mitral valve repair]]: <br>
:❑ Most preferred
❑ [[Mitral valve replacement]]:
:❑ In cases of lateral [[LV]] wall motion abnormality
</div>}}
{{familytree/end}}
{{familytree/end}}



Revision as of 20:37, 22 April 2014


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Mugilan Poongkunran M.B.B.S [3]

Mitral Regurgitation Resident Survival Guide Microchapters
Overview
Causes
FIRE
Complete Diagnostic Approach
Treatment
Acute MR
Chronic MR
Do's
Don'ts

Overview

Mitral regurgitation (MR) refers to a disorder of the heart in which the mitral valve fails to close properly during systole leading to leakage of blood from left ventricle to left atrium during systole and reduction in cardiac output. The symptoms associated with mitral regurgitation are depends on the phase of the disease process. Individuals with acute mitral regurgitation are often gravely ill with significant hemodynamic abnormalities due to decompensated congestive heart failure and low cardiac output that require urgent treatment, whereas individuals with chronic compensated mitral regurgitation may be asymptomatic, with a normal exercise tolerance and no evidence of heart failure.[1] The management of acute MR is mitral valve surgery in most cases, whereas the chronic MR management depends on whether the condition is chronic primary MR (the mitral valve is usually abnormal) or chronic secondary MR (the mitral valve is usually normal) and the severity of the valve anatomy.[2]

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Acute Mitral Regurgitation

Chronic Primary Mitral Regurgitation

Chronic Secondary Mitral Regurgitation

Click here for the complete list of causes.

FIRE: Focused Initial Rapid Evaluation

A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.

Boxes in salmon color signify that an urgent management is needed.

Abbreviations: ARBs: Angiotensin II receptor antagonist; CABG: Coronary artery bypass surgery; HF: Heart failure; IE: Infective endocarditis; LVEF: Left ventricular ejection fraction; LV: Left ventricle; MR: Mitral regurgitation; S1: First heart sound; S2: Second heart sound

 
 
 
 
 
 
 
 
Identify cardinal findings that increase the pretest probability of mitral regurgitation:

Murmur:

❑ Soft, low pitched and decrescendo (in acute MR due to diminished pressure gradient between the left atrium and ventricle)
❑ High pitched and blowing holosystolic murmur best heard over the apex radiating to the axilla and back
❑ Silent (in acute ischemic MR)

Heart sounds:

S1 is diminished (typical)
❑ Wide splitting of S2 (low forward flow causing early A2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have any of the following findings of acute mitral regurgitation with instability?

❑ Sudden onset and rapid progression of pulmonary edema:

Shortness of breath
Tachypnea
Crackles or rales

Signs and symptoms of cardiogenic shock:

Tachycardia
Hypotension
Altered mental status
Oliguria
Diaphoresis
Cold extremities
Peripheral cyanosis
Mottling
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continue with complete diagnostic approach below
 
 
 
 
 
 
 
 
 
 
Initiate resuscitative measures:

❑ Secure airway
❑ Administer O2
❑ Establish 2 wide bore IV access
❑ Establish an arterial line
❑ Connect to ECG monitor
❑ Monitor vitals continuously
❑ Consider ICU admission
❑ Consider mechanical ventilation
❑ Consider pulmonary artery catheterization


Order imaging and blood tests (urgent):
Transthoracic echocardiography (TTE)
Chest X-ray
CBC
Serum electrolytes
Blood cultures (in case of fever)
❑ Serum cardiac troponin I and T
Creatine kinase (CK-MB)
❑ Serum urea and creatinine

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient has any evidence of MR in TTE?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Stabilize the patient:
❑ Initiate medical stabilization:

Vasodilator (IV nitroprusside) PLUS inotropic agents (IV dobutamine)

❑ Establish intra-aortic balloon pump:

❑ If medical therapy is not effective to maintain hemodynamic stability

Initiate treatment for specific etiologies:
Aspirin in case of myocardial infarction
❑ Antibiotics in case of infective endocarditis

 
Consider other possible diagnosis:

Acute respiratory distress syndromeSepsis

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have any findings on TTE that require mitral valve surgery?

❑ Flail mitral leaflet (papillary muscle or chordal rupture)
❑ Any signs of endocarditis

❑ Vegetations on the leaflets
❑ Paravalvular abscess
❑ Moderate to severe ischemic MR
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform mitral valve surgery:

Mitral valve repair:

❑ Most preferred
❑ Done in absence of papillary muscle necrosis

Mitral valve replacement:

❑ Performed in cases of complex MR with extensive tissue destruction
❑ Performed in cases of MR with lateral LV wall motion abnormality
 
Perform reperfusion or revascularization:

❑ In patients with acute coronary syndrome, CABG or coronary angioplasty should be performed
❑ Early reperfusion for myocardial infarction can reduce localized LV remodeling and hence MR

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform reperfusion or revascularization:

❑ Perform CABG or coronary angioplasty at the time of mitral valve surgery in patients with myocardial infarction


Consider cardiac transplantation:
❑ On some occasions with no contraindication for surgery
❑ For patients with severe LV dysfunction

 
 
 
 
 

Complete Diagnostic Approach to Mitral Regurgitation

A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[2].
Abbreviations: AF: Atrial fibrillation; MR: Mitral regurgitation; EKG: Electrocardiogram; EF: Ejection fraction; S1: First heart sound; S2: Second heart sound; S3: Third heart sound; LV: Left ventricle; MVP: Mitral valve prolapse

 
 
 
 
 
 
Characterize the symptoms:

Acute mitral regurgitation:Symptoms of shock and pulmonary edema:

Shortness of breath
Orthopnea
Paroxysmal nocturnal dyspnea
Cough
Altered mental status
Pedel edema
Oliguria
Cyanosis
Pallor
Diaphoresis
Abdominal pain (may be suggestive of mesenteric ischemia)

Symptoms suggestive of precipitating events:

Chest pain (suggestive of myocardial ischemia)
Fever (suggestive of infective endocarditis)
Petechiae, Osler's nodes, Janeway lesions (suggestive of infective endocarditis)

Chronic mitral regurgitation:Asymptomatic

❑ Typical in isolated mild to moderate MR
❑ Severe MR until there is left ventricular failure, pulmonary hypertension or atrial fibrillation

Symptoms associated with decreased forward flow and increased backflow across mitral valve (left ventricular failure):

Exertional dyspnea
Orthopnea
Paroxysmal nocturnal dyspnea
Exercise intolerance
Fatigue
Light-headedness
Exertional syncope
Exertional angina
Cough

Symptoms associated with complications:

Palpitations (suggestive of atrial fibrillation)
Hoarseness (recurrent laryngeal nerve compression due to left atrium enlargement)
Fever (suggestive of infective endocarditis)
Stroke (suggestive of thromboembolism)
Hemoptysis (suggestive of thromboembolism)
Flank pain and hematuria (suggestive of septic emboli or glomerulonephritis)
Seizures (suggestive of thromboembolism)
❑ Symptoms of right heart failure:
Ascites
Pedel edema
Abdominal pain (hepatomegaly)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:

Vital signs:
Pulse

❑ Rapid and thready (in acute MR)
❑ Low volume with brisk upstroke (in chronic MR)
Irregularly irregular pulse (with onset of AF)

Blood pressure

Hypotension (in acute MR)
❑ Normotensive (in chronic MR with preserved ejection fraction)

Temperature

Fever (suggestive of infective endocarditis)

Respiratory rate

Tachypnea (typical)

Skin:
❑ Cool and clammy (in cardiogenic shock)
Cyanosis
Peripheral edema (suggestive of right heart failure)

Cardiovascular system:
Palpation:
Apical impulse

❑ Leftward displacement (in chronic MR due enlargement of the left ventricle)
❑ Hyperdynamic but in normal location (in acute MR)

Thrill (in acute MR and severe chronic MR)
❑ Elevated jugular venous pulse

❑ Sign of elevated right sided pressure
❑ Seen in acute MR and severe chronic MR

Auscultation:
❑ Heart sounds

S1 is diminished (suggestive of MR)
❑ Wide splitting of S2 (low forward flow causing early A2)
❑ Loud and delayed P2 (suggestive of pulmonary hypertension)
❑ New S3 (suggestive of left ventricular dilation)

Murmur

❑ High pitched and blowing holosystolic murmur (typical)
❑ Best heard over the apex radiating to the axilla and back
❑ Starts after S1 and continues up to and sometime beyond and obscuring A2
❑ Other types of murmur
❑ Silent (in cases of acute MR)
❑ Mid to late systolic murmur (in case of papillary muscle prolapse)
❑ Early diastolic murmur (due to large diastolic flow across severe MR)
❑ Mid systolic click (suggestive of mitral valve prolapse)

Respiratory system:
Crackles or rales (suggestive of pulmonary edema)
Tachypnea

Abdominal system:
❑ Hepatojugular reflex
Hepatomegaly
Ascites

Neurological system:
Stroke (in case of thromboembolism)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order electrocardiogram (urgent):

❑ In acute MR

❑ Mostly normal
❑ Findings of myocardial infarction

❑ In chronic MR

❑ Findings of left ventricular hypertrophy with strain
❑ Findings of left atrial enlargement
❑ Findings of pulmonary hypertension
❑ Findings of atrial fibrillation complication
Left atrial enlargement produces a broad, bifid P wave in lead II (P mitrale)

Order chest X-ray (urgent):
Acute MR

❑ Normal size cardiac silhouette
❑ Signs of pulmonary edema

Chronic MR

Cardiomegaly
❑ Signs of pulmonary edema if left ventricle fails
❑ Calcification of the mitral valve annulus
Calcification of the mitral annulus around the margins of the posterior leaflet forming a “C”

Order transthoracic echocardiography (TTE) (urgent):
❑ Confirmatory
❑ To determine severity and assess hemodynamic consequences
❑ To establish etiology
❑ To determine prognosis and evaluate for timing of intervention

Order lab tests:
CBC
Electrolytes
ESR
Serum cardiac troponin I and T
Creatine kinase (CK-MB)
Blood cultures (in case of fever)
❑ Serum urea and creatinine

Other tests:
Transesophageal echocardiography (TEE if TTE is equivocal)
Cardiac catheterization:

❑ In stable acute MR to detect coronary obstruction
❑ To assess hemodynamic status in symptomatic patients when noninvasive tests are inconclusive
❑ To assess the severity when there is discrepancy between noninvasive testing and physical examination

❑ Exercise testing:

❑ Done in asymptomatic severe MR
❑ To confirm the absence of symptoms
❑ To assess the hemodynamic response to exercise

Cardiac MRI

❑ To assess severity when there is a discrepancy between clinical findings and echocardiography
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient has acute or chronic MR?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute MR (Cardinal findings suggestive of acute mitral regurgitation)

❑ Sudden onset and rapid progression of pulmonary edema
Signs and symptoms of cardiogenic shock
❑ Silent to holosystolic murmur on auscultation
❑ Normal ECG
❑ Normal size cardiac silhouette on chest X-ray
Echocardiography findings:

❑ Acute severe mitral regurgitation
❑ Normal left ventricular size
❑ Reduced EF
❑ Ruptured mitral chordae tendinae (flail leaflet)
❑ Ruptured papillary muscle
 
 
 
 
 
Chronic MR (cardinal findings suggestive of chronic mitral regurgitation)

❑ Asymptomatic to chronic symptoms
❑ Pre-existing heart disease
❑ Classic holosystolic murmur on auscultation
ECG findings of left ventricular hypertrophy with strain and left atrial enlargement
Cardiomegaly on chest X-ray
Echocardiography findings:

Mitral regurgitation
Left ventricular dilation
❑ Preserved to decreased EF
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the mitral valve anatomy appear normal in TTE?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic secondary mitral regurgitation
 
Chronic primary mitral regurgitation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Treatment

Treatment of Acute Mitral Regurgitation

Shown below is an algorithm summarizing the approach to the management of acute mitral regurgitation.[1][2].
Abbreviations: IE: Infective endocarditis; LV: Left ventricle; LVEF: Left ventricular ejection fraction; MR: Mitral regurgitation

 
 
 
 
 
 
 
Does the patient has any signs of hemodynamic instability?

❑ Hemodynamic instability

Hypotension
Cold extremities
Peripheral cyanosis
Altered mental status
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
(unstable)
 
 
 
No
(stable)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiate resuscitative measures:

❑ Secure airway
❑ Administer O2
❑ Establish 2 wide bore IV access
❑ Establish an arterial line
❑ Connect to ECG monitor
❑ Monitor vitals continuously
❑ Consider ICU admission
❑ Consider Mechanical ventilation
❑ Consider Pulmonary artery catheterization


Stabilize the patient:
❑ Initiate medical stabilization:

Vasodilator (IV nitroprusside) PLUS inotropic agents (IV dobutamine)

❑ Establish intra-aortic balloon pump:

❑ If medical therapy is not effective to maintain hemodynamic stability
 
 
 
Initiate resuscitative measures:

❑ Administer O2
❑ Establish 2 wide bore IV access
❑ Connect to ECG monitor
❑ Monitor vitals continuously


Initiate medical therapy:

Vasodilator therapy: IV nitroprusside
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ischemic mitral regurgitation
 
 
 
Non-ischemic mitral regurgitation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MR due to heart failure exacerbation(functional MR)
 
MR due to IE (organic MR)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform reperfusion or revascularization surgery:

CABG or coronary angioplasty should be done for acute coronary syndrome
❑ Early reperfusion can reduce localized LV remodeling and hence MR

Consider mitral valve surgery:
❑ Indications of mitral valve surgery in ischemic MR:

Papillary muscle rupture
❑ Moderate to severe ischemic MR who are undergoing CABG

Mitral valve repair:

❑ Most preferred
❑ Done in absence of papillary muscle necrosis

Mitral valve replacement:

❑ In complex MR with extensive destruction
❑ Lateral LV wall motion abnormality

Consider medical therapy:
❑ In cases of reduced LVEF (ischemic cardiomyopathy)
❑ Medications:

Angiotensin converting enzyme inhibitors
Angiotensin II receptor blockers
Beta blockers

Consider cardiac transplantation:


❑ On some occasions with no contraindication for surgery
❑ In patients with severe LV dysfunction

 
Initiate treatment for heart failure:

❑ Click here for acute heart failure resident survival guide

ACE inhibitors or (ARBs) if LVEF is ≤ 40%
Beta blockers
❑ Intravenous inotropic drugs (dobutamine)
Diuretic therapy
❑ IV vasodilators
 

Initiate medical therapy:


❑ Click here for infective endocarditis resident survival guide and antimicrobial treatment


Mitral valve surgery:


❑ Urgent surgery:

❑ Unstable patients
❑ Persistent heart failure
Pulmonary hypertension
❑ Early mitral valve closure

Mitral valve replacement:

❑ Mostly done
❑ Due to extensive tissue destruction

Mitral valve repair:

❑ If less mitral valve destruction
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient show any hemodynamic improvement to medical therapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continue with the heart failure management and have appropriate follow ups to assess the severity of MR
 
Consider mitral valve surgery:

Mitral valve repair:

❑ Most preferred

Mitral valve replacement:

❑ In cases of lateral LV wall motion abnormality
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Treatment of Chronic Mitral Regurgitation

Chronic Primary Mitral Regurgitation

Shown below is an algorithm summarizing the approach to the management of chronic primary mitral regurgitation.[2].
Abbreviations: AF: Atrial fibrillation; IE: Infective endocarditis; LVEF: Left ventricular ejection fraction; LVESD: Left ventricular end systolic dimension; MR: Mitral regurgitation; MVP: Mitral valve proplapse; PASP: Pulmonary artery systolic pressure; RHD: Rheumatic heart disease

 
 
 
 
 
 
Chronic primary mitral regurgitation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe MR:

❑ Etiologies:

❑ Severe MVP with loss of coaptation
RHD with loss of central coaptation
❑ Prior IE
❑ Radiation induced leaflet thickening

Left ventricular dilation
❑ Regurgitation fraction ≥ 50%
❑ Regurgitation volume ≥ 60ml
❑ Effective regurgitation orifice ≥ 0.4cm²
❑ Vena contracta ≥ 0.7cm

 
 
 
Progressive MR (Stage B):

❑ Etiologies:

❑ Severe MVP with normal coaptation
RHD with loss of central coaptation
❑ Prior IE

❑ No Left ventricular dilation
❑ Regurgitation fraction < 50%
❑ Regurgitation volume < 60ml
❑ Effective regurgitation orifice < 0.4cm²
❑ Vena contracta < 0.7cm

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptomatic (Stage D)
 
Asymptomatic (Stage C)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiate medical therapy:

Vasodialators:

❑ Intravenous nitroprusside
Hydralazine

Beta blocker
Diuretics
Calcium channel blocker


Mitral valve surgery:


Mitral valve repair:

❑ Mostly preferred

Mitral valve replacement:

Mechanical valve in patients <65 years who have long-standing AF
Bioprosthetic valves in patients with contraindications to warfarin

Revascularisation:


❑ Concurrent coronary artery disease
❑ Revascularized at the time of mitral valve surgery


Anticoagulation therapy:


Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)
❑ Rheumatic mitral valve disease who have a history of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation

Aspirin:

❑ 75 to 100 mg/day
❑ Recurrent embolism despite adequate anticoagulation

Endocarditis prophylaxis:


Initiate infective endocarditis antimicrobial prophylaxis after mitral valve surgery

 
Mitral valve surgery:

❑ Performed in the following patients:

LVEF 30 to ≤60% OR LVESD ≥ 40mm (Stage C2)
LVEF >60% AND LVESD < 40mm (Stage C1)
❑ With likelihood of successful repair > 95%
❑ With expected mortality < 1%
❑ New onset AF OR PASP > 50mmHg (Stage C1)
❑ With likelihood of successful repair > 95%
❑ With expected mortality < 1%

Mitral valve repair:

❑ Mostly preferred

Mitral valve replacement:

Mechanical valve in patients <65 years who have long-standing AF
Bioprosthetic valves in patients with contraindications to warfarin

Revascularization:


❑ Concurrent coronary artery disease
❑ Revascularized at the time of mitral valve surgery


Periodic monitoring:


❑ In stage C1 patients with the following:

❑ With likelihood of successful repair < 95%
❑ With expected mortality > 1%

❑ Clinical evaluation:

❑ Every 3-6 months

Echocardiography:

❑ Every 6 months

Anticoagulation therapy:


Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)
❑ Rheumatic mitral valve disease who have a history of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation

Aspirin:

❑ 75 to 100 mg/day
❑ Recurrent embolism despite adequate anticoagulation

Endocarditis prophylaxis:


Initiate infective endocarditis antimicrobial prophylaxis for patients undergoing mitral valve surgery

 
Periodic monitoring:

❑ Clinical evaluation:

❑ Every 3-6 months

Echocardiography:

❑ Every 6 months

Anticoagulation therapy:


Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)
❑ Rheumatic mitral valve disease who have a history of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation

Aspirin:

❑ 75 to 100 mg/day
❑ Recurrent embolism despite adequate anticoagulation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Chronic Secondary Mitral Regurgitation

Shown below is an algorithm summarizing the approach to the management of chronic secondary mitral regurgitation.[2].

Abbreviations: AF: Atrial fibrillation; CAD: Coronary artery disease; HF: Heart failure; IE: Infective endocarditis; LV: Left ventricle; MR: Mitral regurgitation

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic secondary mitral regurgitation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heart failure treatment:

❑ Click here for heart failure resident survival guide

ACE inhibitors
ARBs
Beta blockers
❑ Intravenous inotropic drugs (dobutamine)
Diuretictherapy
❑ IV vasodilators
 
CAD treatment:

❑ Click here for coronary artery disease medical therapy

Aspirin
ACE inhibitors
Beta blockers

Coronary angiography
❑ Click here for revascularization therapy

 
Cardiac resynchronization therapy:

Cardiac resynchronization therapy with biventricular pacing:

❑ In functional MR patients with ventricular dyssynchrony
❑ Reduce LV end-systolic and end-diastolic dimensions
❑ Reduce mitral regurgitant jet area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe MR:

❑ Echo findings:

❑ Regional wall motion abnormalities with severe tethering of mitral leaflet
❑ Annular dilation with severe loss of central coaptation of the mitral leaflets

❑ LV dilation and systolic dysfunction due to primary myocardial disease
❑ Regurgitation fraction ≥ 50%
❑ Regurgitation volume ≥ 30ml
❑ Effective regurgitation orifice ≥ 0.2 cm²

 
 
 
Progressive MR (Stage B):

❑ Echo findings:

❑ Regional wall motion abnormalities with mild tethering of mitral leaflet
❑ Annular dilation with mild loss of central coaptation of the mitral leaflets

❑ LV dilation and systolic dysfunction due to primary myocardial disease
❑ Regurgitation fraction < 50%
❑ Regurgitation volume < 30ml
❑ Effective regurgitation orifice < 0.2 cm²

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage D: Symptomatic (HF symptoms due to MR persist even after revascularization and medical therapy)
 
Stage C: Asymptomatic (HF and coronary ischemia symptoms respond to revascularization and medical herapy)
 
HF and coronary ischemia symptoms respond to revascularization and medical herapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitral valve surgery:

Mitral valve repair:

❑ Mostly preferred

Mitral valve replacement:

Mechanical valve in patients <65 years who have long-standing AF
Bioprosthetic valves in patients with contraindications to warfarin

Anticoagulation therapy:


Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)
❑ History of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation

Aspirin:

❑ 75 to 100 mg/day
❑ Recurrent embolism despite adequate anticoagulation

Endocarditis prophylaxis:


Initiate infective endocarditis antimicrobial prophylaxis

 
Periodic monitoring:

❑ Clinical evaluation:

❑ Every 3-6 months

Echocardiography:

❑ Every 6 months

Mitral valve surgery:


❑ Only in patients undergoing other cardiac surgery
Mitral valve repair:

❑ Mostly preferred

Mitral valve replacement:

Mechanical valve in patients <65 years who have long-standing AF
Bioprosthetic valves in patients with contraindications to warfarin

Anticoagulation therapy:


Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)
❑ History of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation

Aspirin:

❑ 75 to 100 mg/day
❑ Recurrent embolism despite adequate anticoagulation

Endocarditis prophylaxis:


Initiate infective endocarditis antimicrobial prophylaxis for patients undergoing mitral valve surgery

 
Periodic monitoring:

❑ Clinical evaluation:

❑ Every 3-6 months

Echocardiography:

❑ Every 6 months

Mitral valve surgery:


❑ Only in patients undergoing other cardiac surgery
Mitral valve repair:

❑ Mostly preferred

Mitral valve replacement:

Mechanical valve in patients <65 years who have long-standing AF
Bioprosthetic valves in patients with contraindications to warfarin

Anticoagulation therapy:


Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)
❑ History of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation

Aspirin:

❑ 75 to 100 mg/day
❑ Recurrent embolism despite adequate anticoagulation

Endocarditis prophylaxis:


Initiate infective endocarditis antimicrobial prophylaxis for patients undergoing mitral valve surgery

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Do's

  • Always consult a multidisciplinary heart valve team for patients with acute MR, severe chronic MR and with multiple comorbidities.
  • Consider vasodilator therapy in patients with chronic MR based upon the presence or absence of symptoms and the functional state of the left ventricle.
  • Always consider patients with chronic MR who become symptomatic to be candidates for corrective mitral surgery.
  • Perform mitral valve repair for patients with chronic severe primary MR limited to the posterior leaflet.

Don'ts

  • Don't initiate vasodilator therapy for normotensive asymptomatic patients with chronic primary MR (stages B and C1) and normal systolic LV function.
  • Don't recommend cardiovascular magnetic resonance (CMR) for routine diagnosis of MR.
  • Don't prefer mitral valve repair to replacement to chronic severe primary MR patients involving the anterior leaflet or both leaflets when a successful and durable repair cannot be accomplished.
  • Don't perform mitral valve replacement in patients with isolated severe primary MR limited to less than one half of the posterior leaflet unless mitral valve repair has been attempted and was unsuccessful.
  • Don't perform coronary angiography before valve surgery in patients who are hemodynamically unstable.
  • Avoid coronary angiography in patients of acute coronary syndrome complicated by severe acute mitral regurgitation.

References

  1. 1.0 1.1 Stout KK, Verrier ED (2009). "Acute valvular regurgitation". Circulation. 119 (25): 3232–41. doi:10.1161/CIRCULATIONAHA.108.782292. PMID 19564568.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000029. PMID 24589852.
  3. Anderson Y, Wilson N, Nicholson R, Finucane K (2008). "Fulminant mitral regurgitation due to ruptured chordae tendinae in acute rheumatic fever". J Paediatr Child Health. 44 (3): 134–7. doi:10.1111/j.1440-1754.2007.01214.x. PMID 17854408.
  4. Grinberg AR, Finkielman JD, Piñeiro D, Festa H, Cazenave C (1998). "Rupture of mitral chorda tendinea following blunt chest trauma". Clin Cardiol. 21 (4): 300–1. PMID 9580528.
  5. Grenadier E, Alpan G, Keidar S, Palant A (1983). "The prevalence of ruptured chordae tendineae in the mitral valve prolapse syndrome". Am Heart J. 105 (4): 603–10. PMID 6837414.
  6. Otto CM (2001). "Clinical practice. Evaluation and management of chronic mitral regurgitation". N Engl J Med. 345 (10): 740–6. doi:10.1056/NEJMcp003331. PMID 11547744.


Template:WikiDoc Sources